Text Correction
In the original publication [1], the catalogue number of anti-ß-galactosidase was cited as “Cat# sc-65670, RRID:AB_831022IBA1”, instead of the correct product information, “Cat# sc-377257”.
A correction has been made to the respective sentence in Section 2.11 “Western Blotting”, Paragraph 1:
“Membranes were blocked in PBST (PBS with 0.1% Tween) containing 5% non-fat dry milk for 90 min and incubated overnight at 4 °C with primary antibodies: anti-ß-galactosidase (Santa Cruz Biotechnology, Dallas, TX, USA, Cat# sc-377257), anti-IκBα (Santa Cruz Biotechnology, Dallas, TX, USA, Cat# sc-1643, RRID:AB_627772), and anti-IL-1ß (Santa Cruz Biotechnology, Dallas, TX, USA, Cat# sc-52012, RRID:AB_629741)”.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Borgonetti, V.; Galeotti, N. Rosmarinic Acid Reduces Microglia Senescence: A Novel Therapeutic Approach for the Management of Neuropathic Pain Symptoms. Biomedicines 2022, 10, 1468. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.